Theratechnologies Says Phasing Down Of Research Activities Is Aligned With The Co's Focus On Its Commercial Business And Will Further Optimize Its Organizational Cost Structure; Results In A Restructuring Charge Of ~$625,000 In Cash Charges Related To Severance And Other Expenses And ~$770,000 In Non-Cash Charges
$THTX
Biotechnology: Pharmaceutical Preparations
Health Care
Theratechnologies Says Phasing Down Of Research Activities Is Aligned With The Co's Focus On Its Commercial Business And Will Further Optimize Its Organizational Cost Structure; Results In A Restructuring Charge Of ~$625,000 In Cash Charges Related To Severance And Other Expenses And ~$770,000 In Non-Cash Charges